

Informazione Regolamentata n. 20106-25-2024	Data/Ora Inizio Diffusione 18 Giugno 2024 10:34:05	Euronext Star Milan
---	---	---------------------

Societa' : PHARMANUTRA

Identificativo Informazione  
Regolamentata : 192355

Utenza - Referente : PHARMANUTRAN04 - Roberto Lacorte

Tipologia : REGEM

Data/Ora Ricezione : 18 Giugno 2024 10:34:05

Data/Ora Inizio Diffusione : 18 Giugno 2024 10:34:05

Oggetto : PHARMANUTRA S.P.A.: THE DISTRIBUTION  
OF IRON-BASED DIETARY SUPPLEMENTS  
KICKS OFF IN MEXICO

*Testo del comunicato*

Vedi allegato

## PHARMANUTRA S.P.A.: THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO

**Partner SMS Pharma will market the three products in the SiderAL® line under the trade name Sucrosom®, which is based on our ground-breaking, patented Sucrosomial® Technology.**

Pisa, June 18 2024 – This is a new step forward in the steady expansion into foreign markets of [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), the company established in 2003 by brothers Andrea and Roberto Lacorte, specializing in medical devices for muscles and joints and mineral-based dietary supplements. Last month, in Mexico City, PharmaNutra S.p.A.'s International Dept. Team participated in the launch event for the three products that will be distributed in Mexico starting this month. This follows the contract signed in November 2022 with its partner SMS Pharma, a group of companies founded in 2009 specializing in the development and implementation of business models and demand generation, with a focus on the market of pharmaceutical and healthcare products.

The products -Sucrosom® F15 30 capsules (SiderAL® Forte 15mg), Sucrosom® Fol 20mg 20 sticks (SiderAL® Folico 20mg) and Sucrosom® Gotas (SiderAL® P Drops)- are those of the line of iron-based dietary supplements on the Italian and international market under the SiderAL® brand name and made on the basis of Sucrosomial® Technology, the innovative delivery system, designed and patented by PharmaNutra, which improves absorption and tolerability of microelements, macroelements and phytoextracts essential for the human body. They will be marketed in the main urban areas of Mexico; this country, thanks to specific and well-targeted measures implemented by the authorities involved, has recently been devoting considerable attention to the problem of iron deficiency in the population.

PharmaNutra's presence in the Central American region includes, along with Mexico, countries such as El Salvador, Panama, Costa Rica and Guatemala, thanks to the contract that was signed in March 2023 with KOLPharma for the on-site distribution of SiderAL® Forte and SiderAL® Folico products, which will be marketed starting early next year.

**Carlo Volpi, Chief Operating Officer of PharmaNutra S.p.A. states:** *"We are very pleased to announce the launch of the three Sucrosomial® Iron products in Mexico, one of the most important countries in Central America. In Mexico, there has been considerable attention devoted lately to the problem of iron deficiency. If this problem is addressed in time and correctly, the spread of other more serious diseases that pose a far greater impact on the local population can be prevented. This factor, along with the enthusiasm for our products displayed by our*

partner's sales network, gives us confidence about business development in a country that has a truly remarkable potential”.

#### PharmaNutra S.p.A.

Founded and led by President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops one-of-a-kind dietary supplements and innovative medical devices, handling the entire production process, from the manufacturing of proprietary raw materials to the finished product. PharmaNutra is a leading manufacturer of iron-based dietary supplements with its SiderAL® brand, where it boasts important Sucrosomial® Technology patents, and is considered one of the top emerging players in the field of medical devices for restoring joint functions through its Cetilar® brand. There is considerable scientific evidence, including 120 publications, to support the effectiveness of its products. In Italy, a network of over 160 Scientific Sales Representatives handles the sales activity. They serve the health professionals and are dedicated to the exclusive sale of these products to pharmacies and drugstores nation-wide. Overseas sales of the products are guaranteed in over 71 countries through 45 partners selected from among the top pharmaceutical companies. Over the years, the Group has developed a precise strategy for the management and production of intellectual property based on the integrated management of every component: the manufacturing of its own raw materials, patents, trademarks and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

#### For further information:

**PharmaNutra S.p.A.**

**Via Campodavella, 1 - 56122 Pisa**

**Tel. +39 050 7846500**

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

**Internal Press Office**

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

**Via Santa Radegonda, 16 - 20121 Milan**

**Tel. +39 02 83635708**

**Matteo Russo**

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

**Cristina Tronconi**

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-25-2024

Numero di Pagine: 4